A time to keep and a time to cast away categories of tumor response

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3109-3111

  Maitland, Michael L ^a   Bies, Robert R ^b   Barrett, Jeffrey S ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DRUG SCREENING; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR GENETICS; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SIMULATION; SOLID TUMOR; TUMOR GROWTH; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051764363     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.3887     Document Type: Editorial

References (18)

1. Oxnard G.R., Zhao B., Sima C.S., et al: Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 29:3114-3119, 2011
2. Eisenhauer E.A., Therasse P., Bogaerts J., et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
3. Sheiner L.B.: Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275-291, 1997
4. Moertel C.G., Hanley J.A.: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394, 1976
5. Miller A.B., Hoogstraten B., Staquet M., et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981 (Pubitemid 11167383)
6. Simon R.: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
7. Ratain M.J., Eisen T., Stadler W.M., et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006 (Pubitemid 46630627)
8. Bruno R., Claret L.: On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther 86:136-138, 2009
9. Barrett J.S., Gupta M., Mondick J.T.: Model-based drug development applied to oncology. Expert Opin Drug Discov 2:185-209, 2007 (Pubitemid 47073087)
10. Wang Y., Sung C., Dartois C., et al: Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167-174, 2009
11. Claret L., Girard P., Hoff P.M., et al: Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009
12. Frances N., Claret L., Bruno R., et al: Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother Pharmacol [epub ahead of print on April 8, 2011]
13. Stein W.D., Gulley J.L., Schlom J., et al: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917, 2011
14. Tham L.S., Wang L., Soo R.A., et al: A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14:4213-4218, 2008
15. Maitland M.L., Hudoba C., Snider K.L., et al: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 16:5296-5302, 2010
16. Yap T.A., Sandhu S.K., Workman P., et al: Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514-523, 2010
17. Bruno R., Lu J.F., Sun Y.N., et al: A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol 51:6-8, 2010
18. Barrett J.S., Mondick J.T., Narayan M., et al: Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak 8:6, 2008